New drug development for pediatric oncology

Investigational New Drugs

Volumn 14, Issue 1, 1996, Pages 1-10

  Weitman, Steven ^a,d   Carlson, Lisa ^b   Pratt, Charles B ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZAURIDINE; ALANOSINE; ANCITABINE; ANTINEOPLASTIC AGENT; BISANTRENE; CARBOPLATIN; DIANHYDROGALACTITOL; DIAZIQUONE; DOCETAXEL; FAZARABINE; FOLIC ACID ANTAGONIST; INDOMETACIN; MITOFLAXONE; MITOXANTRONE; PACLITAXEL; PIRITREXIM; RALTITREXED; RAZOXANE; SPIROMUSTINE; TIAZOFURIN; TOPOTECAN; TRIMETREXATE; ZORUBICIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOXICITY; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PERICARDITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

EID: 0029790039     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00173677     Document Type: Review

References (12)

1. Lukens JN: Progress resulting from clinical trials. Cancer 74:2710-2718, 1994
2. Pratt CB: The conduct of phase I-II clinical trials in children with cancer. Med Ped Oncol 19:304-309, 1991
3. Leventhal BG, Graham ML: Clinical trials in pediatric oncology. Sem Oncol 15:482-487, 1988
4. Ungerleider RS, Marsoni S: Phase I and II trials in pediatric cancer patients: a rational. In: Poplack DG, Massimo L, Cornaglia-Ferraris P (eds) The Role of Pharmacology in Pediatric Oncology. Boston: Kluwer Academic, 1987, pp 159-170.
5. Furman WL, Pratt CB, Rivera GK, Krischer JP, Kamen BK, Vietti TJ: Mortality in pediatric phase I clinical trials. J Natl Cancer Inst 81:1193-1194, 1989
6. Estey EE, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R: Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105-1115, 1986
7. Von Hoff DD, Turner J: Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115-122, 1991
8. Bacha DM, Caparros-Sison B, Allen JA, Walker R, Tan CTC: Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 70:865-869, 1986
9. Gaynon PS, Ettinger LJ, Moel D, Siegel SE, Baum ES, Krivit W, Hammond GD: Pediatric phase I trial of carboplatin: A Childrens Cancer Study Group report. Cancer Treat Rep 71:1039-1042, 1987
10. Ungerleider RS, Pratt CB, Vietti TJ, Holcenberg JS, Kamen BA, Glaubiger DL, Cohen LF: Phase I trial of mitoxantrone in children. Cancer Treat Rep 69:403-407, 1985
11. Pappo AS, Vats T, Williams TE, Bernstein M, Kamen BA: Phase I trial of trimetrexate in pediatric solid tumors: A Pediatric Oncology Group study. Med Pediatr Oncol 21:280-282, 1993
12. Hurwitz CA, Relling MV, Weitman SD, Ravindranath Y, Vietti TJ, Strother DR, Ragab AH, Pratt CB: Phase I trial of taxol in children with refractory solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 11:2324-2329, 1993